

David R Lairson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8275115/publications.pdf>

Version: 2024-02-01

81
papers

2,195
citations

304743

22
h-index

243625

44
g-index

81
all docs

81
docs citations

81
times ranked

2901
citing authors

#	ARTICLE	IF	CITATIONS
1	Palliative medicine integration in the USA: cancer centre executives' attitudes. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, 199-208.	1.6	2
2	Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100143.	2.6	25
3	Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001-2017. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 155.	2.2	48
4	An economic and disease transmission model of human papillomavirus and oropharyngeal cancer in Texas. <i>Scientific Reports</i> , 2021, 11, 1802.	3.3	0
5	A stepped randomized trial to promote colorectal cancer screening in a nationwide sample of U.S. Veterans. <i>Contemporary Clinical Trials</i> , 2021, 105, 106392.	1.8	2
6	Economic Evaluation of Web- versus Telephone-based Interventions to Simultaneously Increase Colorectal and Breast Cancer Screening Among Women. <i>Cancer Prevention Research</i> , 2021, 14, 905-916.	1.5	1
7	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. <i>JAMA Network Open</i> , 2021, 4, e2124502.	5.9	58
8	Cost of treating recurrent respiratory papillomavirus in commercially insured and medicaid patients. <i>Laryngoscope</i> , 2020, 130, 1186-1194.	2.0	5
9	An RCT to Increase Breast and Colorectal Cancer Screening. <i>American Journal of Preventive Medicine</i> , 2020, 59, e69-e78.	3.0	10
10	Parental intent to initiate and complete the human papillomavirus vaccine series in the USA: a nationwide, cross-sectional survey. <i>Lancet Public Health</i> , The, 2020, 5, e484-e492.	10.0	72
11	Lifetime health care costs of oropharyngeal cancer for commercially insured patients in the United States. <i>Head and Neck</i> , 2020, 42, 2321-2329.	2.0	0
12	Economic Evaluation of Tailored Web versus Tailored Telephone-Based Interventions to Increase Colorectal Cancer Screening among Women. <i>Cancer Prevention Research</i> , 2020, 13, 309-316.	1.5	4
13	Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer. <i>Journal of Racial and Ethnic Health Disparities</i> , 2019, 6, 133-142.	3.2	6
14	Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review. <i>Pharmacoeconomics</i> , 2019, 37, 1421-1449.	3.3	8
15	Direct medical cost of oropharyngeal cancer among patients insured by Medicaid in Texas. <i>Oral Oncology</i> , 2019, 96, 21-26.	1.5	3
16	Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e616-e623.	0.4	1
17	Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 294.e17-294.e25.	1.6	5
18	Projected oropharyngeal carcinoma incidence among middle-aged US men. <i>Head and Neck</i> , 2019, 41, 3226-3234.	2.0	33

#	ARTICLE	IF	CITATIONS
19	Spatio-Temporal Variation of Gender-Specific Hypertension Risk: Evidence from China. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4545.	2.6	4
20	Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas. <i>Journal of Lower Genital Tract Disease</i> , 2019, 23, 102-109.	1.9	2
21	Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995â€“2013: Findings from Texas and national SEER areas. <i>Cancer Epidemiology</i> , 2019, 58, 89-97.	1.9	5
22	Implementation costs of a multi-component program to increase human papillomavirus (HPV) vaccination in a network of pediatric clinics. <i>Journal of Applied Research on Children</i> , 2019, 10, .	0.2	0
23	Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma. <i>Annals of Hematology</i> , 2018, 97, 851-863.	1.8	5
24	Cost-Effectiveness of Community Interventions for Colorectal Cancer Screening: Low-Income Hispanic Population. <i>Health Promotion Practice</i> , 2018, 19, 863-872.	1.6	12
25	Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas. <i>Gynecologic Oncology</i> , 2018, 148, 342-348.	1.4	17
26	Benefits of stroke treatment delivered using a mobile stroke unit trial. <i>International Journal of Stroke</i> , 2018, 13, 321-327.	5.9	50
27	Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1156-1164.	0.9	8
28	Reply to â€œLetter to the Editor in response to the article, â€˜The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysisâ€™â€•. <i>Oral Oncology</i> , 2018, 86, 307.	1.5	0
29	Age-Structured Population Modeling of HPV-related Cervical Cancer in Texas and US. <i>Scientific Reports</i> , 2018, 8, 14346.	3.3	7
30	A Randomized Trial to Compare a Tailored Web-Based Intervention and Tailored Phone Counseling to Usual Care for Increasing Colorectal Cancer Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1433-1441.	2.5	21
31	Risks of Major Longâ€“Term Side Effects Associated with Androgenâ€“Deprivation Therapy in Men with Prostate Cancer. <i>Pharmacotherapy</i> , 2018, 38, 999-1009.	2.6	50
32	Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients. <i>Pharmacoeconomics</i> , 2018, 36, 1355-1365.	3.3	4
33	The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2018, 82, 91-99.	1.5	77
34	Budget Impact Analysis of Against Colorectal Cancer In Our Neighborhoods (ACCION): A Successful Community-Based Colorectal Cancer Screening Program for a Medically Underserved Minority Population. <i>Value in Health</i> , 2017, 20, 809-818.	0.3	12
35	Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. <i>Gynecologic Oncology</i> , 2017, 145, 108-113.	1.4	28
36	The cost of developing a computerized tailored interactive multimedia intervention vs. a print based Photonovella intervention for HPV vaccine education. <i>Evaluation and Program Planning</i> , 2017, 63, 1-6.	1.6	9

#	ARTICLE	IF	CITATIONS
37	The cost of implementing two small media interventions to promote HPV vaccination. <i>Preventive Medicine</i> , 2017, 99, 277-281.	3.4	7
38	Medical Care Cost of Oropharyngeal Cancer among Texas Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1443-1449.	2.5	26
39	Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort. <i>Medical Oncology</i> , 2017, 34, 153.	2.5	7
40	Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 831-843.	0.9	14
41	Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 64-73.	0.9	6
42	Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. <i>Oncotarget</i> , 2017, 8, 112516-112529.	1.8	32
43	Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer. <i>Women's Health Issues</i> , 2016, 26, 574-583.	2.0	2
44	Patterns of Treatment Sequences in Chemotherapy and Targeted Biologics for Metastatic Colorectal Cancer: Findings from a Large Community-Based Cohort of Elderly Patients. <i>Drugs - Real World Outcomes</i> , 2016, 3, 69-82.	1.6	17
45	Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Population-Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992-2009. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1570-1582.	2.6	11
46	The Effect of National Cancer Screening on Disparity Reduction in Cancer Stage at Diagnosis by Income Level. <i>PLoS ONE</i> , 2015, 10, e0136036.	2.5	21
47	Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. <i>Value in Health</i> , 2015, 18, 1070-1078.	0.3	10
48	Against Colorectal Cancer in Our Neighborhoods, a Community-Based Colorectal Cancer Screening Program Targeting Low-Income Hispanics. <i>Health Promotion Practice</i> , 2015, 16, 656-666.	1.6	19
49	Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007-2010 after the 2006 introduction of bevacizumab. <i>Lung Cancer</i> , 2015, 90, 442-450.	2.0	10
50	Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer. <i>Value in Health</i> , 2015, 18, 387-395.	0.3	18
51	Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review. <i>Pharmacoeconomics</i> , 2015, 33, 1155-1185.	3.3	16
52	Estimating development cost of an interactive website based cancer screening promotion program. <i>Evaluation and Program Planning</i> , 2015, 50, 56-62.	1.6	4
53	Cost-Effectiveness of a standard intervention versus a navigated intervention on colorectal cancer screening use in primary care. <i>Cancer</i> , 2014, 120, 1042-1049.	4.1	37
54	Cost-Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer. <i>Pharmacoeconomics</i> , 2014, 32, 1005-1013.	3.3	11

#	ARTICLE	IF	CITATIONS
55	Cost-Utility Analysis of Platinum-Based Chemotherapy versus Taxane and Other Regimens for Ovarian Cancer. <i>Value in Health</i> , 2014, 17, 34-42.	0.3	10
56	Cervical Cancer Screening with AMIGAS. <i>American Journal of Preventive Medicine</i> , 2014, 46, 617-623.	3.0	9
57	AMIGAS: A multicity, multicomponent cervical cancer prevention trial among Mexican American women. <i>Cancer</i> , 2013, 119, 1365-1372.	4.1	92
58	Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. <i>Medical Oncology</i> , 2013, 30, 440.	2.5	7
59	Geographic Variation and Sociodemographic Disparity in the Use of Oxaliplatin-Containing Chemotherapy in Patients With Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2013, 12, 113-121.	2.3	23
60	The cost of implementing a 2-1-1 call center-based cancer control navigator program. <i>Evaluation and Program Planning</i> , 2013, 39, 51-56.	1.6	11
61	Clinical and Economic Outcomes Associated with Adjuvant Chemotherapy in Elderly Patients with Early Stage Operable Breast Cancer. <i>Value in Health</i> , 2012, 15, 72-80.	0.3	13
62	Economic Methods in the Century Trial—a Comprehensive Lifestyle Modification Study for Managing Coronary Artery Disease. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 333-336.	2.4	2
63	Socioeconomic status, health care use, and outcomes: Persistence of disparities over time. <i>Epilepsia</i> , 2011, 52, 957-964.	5.1	70
64	Cost-effectiveness of targeted versus tailored interventions to promote mammography screening among women military veterans in the United States. <i>Evaluation and Program Planning</i> , 2011, 34, 97-104.	1.6	14
65	A Randomized Controlled Trial of a Tailored Interactive Computer-Delivered Intervention to Promote Colorectal Cancer Screening: Sometimes More is Just the Same. <i>Annals of Behavioral Medicine</i> , 2011, 41, 284-299.	2.9	72
66	Cost Effectiveness of Interventions to Promote Screening for Colorectal Cancer: A Randomized Trial. <i>Journal of Preventive Medicine and Public Health</i> , 2011, 44, 101-110.	1.9	21
67	Sociodemographic disparities in epilepsy care: Results from the Houston/New York City health care use and outcomes study. <i>Epilepsia</i> , 2009, 50, 1040-1050.	5.1	73
68	Concordance of survey and billing data in a study of outpatient healthcare cost and utilization among epilepsy patients. <i>Epilepsy Research</i> , 2009, 87, 59-69.	1.6	16
69	Cost-effectiveness of targeted and tailored interventions on colorectal cancer screening use. <i>Cancer</i> , 2008, 112, 779-788.	4.1	48
70	Promoting Regular Mammography Screening I. A Systematic Assessment of Validity in a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 333-346.	6.3	21
71	Promoting Regular Mammography Screening II. Results From a Randomized Controlled Trial in US Women Veterans. <i>Journal of the National Cancer Institute</i> , 2008, 100, 347-358.	6.3	35
72	Estimating Development Cost for a Tailored Interactive Computer Program to Enhance Colorectal Cancer Screening Compliance. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2006, 13, 476-484.	4.4	14

#	ARTICLE	IF	CITATIONS
73	Cost-effectiveness of alternate contact protocols and costs of mammography promotion interventions for women veterans. <i>Evaluation and Program Planning</i> , 2006, 29, 120-129.	1.6	1
74	Determinants of the demand for breast cancer screening among women veterans in the United States. <i>Social Science and Medicine</i> , 2005, 61, 1608-1617.	3.8	44
75	Development costs of a computer-generated tailored intervention. <i>Evaluation and Program Planning</i> , 2004, 27, 161-169.	1.6	18
76	Prevention of Herpes Simplex Virus Eye Disease. <i>JAMA Ophthalmology</i> , 2003, 121, 108.	2.4	76
77	The Cost of Epilepsy in the United States: An Estimate from Population-Based Clinical and Survey Data. <i>Epilepsia</i> , 2000, 41, 342-351.	5.1	504
78	Estimating the Cost of Epilepsy. <i>Epilepsia</i> , 1999, 40, 8-13.	5.1	63
79	Cost-Effectiveness of Alternative Methods for Diabetic Retinopathy Screening. <i>Diabetes Care</i> , 1992, 15, 1369-1377.	8.6	72
80	Estimating the cost of education and counseling programs. <i>Patient Education and Counseling</i> , 1991, 18, 179-188.	2.2	3
81	Prescribed Medicines. <i>Journal of Pharmaceutical Marketing and Management</i> , 1988, 3, 19-36.	0.1	1